New drug trial aims to rescue failing lungs after transplant
NCT ID NCT07538336
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a one-time infusion of emapalumab in 40 adults who had a lung transplant and now have a sudden drop in lung function (acute lung allograft dysfunction). The goal is to see if the drug can help their lungs recover to near-normal function within 90 days. Emapalumab blocks a protein that may be causing the damage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
emapalumab
What this could lead to
If it works, this could point toward a treatment for sudden lung function decline after lung transplant, helping patients breathe better without needing a new transplant.
What could go wrong
This is a small, early-phase trial with only 40 people. The drug may not improve lung function, and there are risks like serious infections since emapalumab suppresses the immune system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States